ERBB3 and lung carcinoma: Nonetheless, MET amplification is recognized as a mechanism of resistance following small-molecule inhibitor targeting of EGFR mutant lung cancer, and conversely, EGFR and HER3 amplification or mutation have been observed as resistance mechanisms to Met inhibition in human cancers [26–28].